Ragistomig

Clinical Trials

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Posted: 2021/02/21

Sponsor:ABL Bio, Inc.

ID:NCT04762641

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

I-Mab Prioritizes Givastomig for Gastric Cancer Treatment, Pauses Uliledlimab Development

5 months ago

I-Mab is prioritizing givastomig, a CLDN18.2 x 4-1BB bispecific antibody, as its lead clinical program for metastatic gastric cancers.

Immunic's Vidofludimus Calcium Advances in MS Trials; I-Mab's Immunotherapies Show Promise

7 months ago

Immunic's phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis (RMS) continues as planned after a positive interim futility analysis.

I-Mab Announces Pipeline Progress and Financial Results for 1H 2024

9 months ago

I-Mab completed the divestiture of its China operations, streamlining the organization and transitioning to a U.S.-based operating model.

I-Mab Advances Immunotherapy Pipeline with Uliledlimab, Givastomig, and Ragistomig

a year ago

I-Mab is preparing to file an IND for uliledlimab in combination with chemotherapy and checkpoint inhibitors for newly diagnosed NSCLC patients in 1H 2024.

Drug Development Updates

Overview

Background

Indication

Associated Conditions